Georgios B.
- Country
- Greece
- Department
- 3rd Academic Department of Internal Medicine , Gastroenterology Unit
Research Overview
- Efficacy and Safety Evaluation of Budoprutug (TNT119) in Patients with Systemic Lupus Erythematosus
- Evaluation of Budoprutug (TNT119) Efficacy and Safety in Patients with Systemic Lupus Erythematosus
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
Data & Insights
Has run more than one trial at 390 of 779 partner sites.
Specializations
Thoracic Oncology
Non-small cell lung cancer, small cell lung cancer, and other advanced solid tumors are central to this investigator’s trial portfolio, with additional involvement in melanoma, bladder cancer, and gastroesophageal junction cancer. The research landscape also includes biomarker-defined disease such as EGFR-mutated, ALK-positive, KRAS G12C-mutant, HER2-altered, and PD-L1-selected tumors.
- Advanced and metastatic lung cancer
- Targeted and biomarker-driven solid tumors
- Melanoma and other advanced malignancies
Work across the affiliated hospitals in Athens and Thessaloniki supports a strong focus on precision oncology and treatment innovation in difficult-to-treat cancers.
Inflammatory Bowel and Gastrointestinal Disease
The investigator is active in Crohn’s disease, ulcerative colitis, pouchitis, coeliac disease, and eosinophilic esophagitis, reflecting a broad therapeutic interest in chronic inflammatory disorders of the digestive tract. The portfolio also extends to non-alcoholic steatohepatitis and alcohol-related liver disease.
- Crohn’s disease and fistulizing disease
- Ulcerative colitis and pouchitis
- Inflammatory and metabolic liver disease
These areas indicate sustained involvement in immune-mediated gastrointestinal disease and liver-focused therapeutic development.
Autoimmune and Rheumatologic Disorders
Clinical research activity includes systemic lupus erythematosus, sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, antiphospholipid syndrome, and vasculitis. The portfolio also covers myositis, sarcoidosis, and other connective tissue diseases.
- Systemic lupus erythematosus
- Sjögren’s syndrome and systemic sclerosis
- Rheumatoid arthritis and vasculitic disease
The therapeutic emphasis is on immune modulation for chronic systemic inflammatory disease, including conditions with organ involvement and persistent symptom burden.
Hematology and Blood Disorders
The investigator’s hematology portfolio spans diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, myelofibrosis, and myelodysplastic syndromes. Additional interest is seen in hemophilia, thalassemia, immune thrombocytopenia, and paroxysmal nocturnal hemoglobinuria.
- Lymphoid and myeloid malignancies
- Plasma cell disorders and myelofibrosis
- Inherited and acquired bleeding disorders
This mix of malignant and non-malignant hematologic conditions highlights engagement with both targeted cancer therapy and supportive innovation in blood disorders.
Cardiometabolic, Respiratory, and Renal Medicine
Trial involvement also covers atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, ischemic stroke, hypertension, type 2 diabetes, obesity, chronic kidney disease, IgA nephropathy, idiopathic pulmonary fibrosis, asthma, COPD, and bronchiectasis.
- Cardiovascular prevention and heart failure
- Diabetes, obesity, and kidney disease
- Chronic lung disease and fibrotic respiratory disorders
There is also involvement in infectious disease settings such as COVID-19, sepsis, and bacterial pneumonia, broadening the therapeutic scope into acute internal medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.